MDD Management Strategies Clinical Trial
— PismaEPOfficial title:
Assessment of MDD Management Strategies in Andalusia: A Sub-analysis of the PismaEP Study
| Verified date | August 2014 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Spain: Spanish Agency of Medicines |
| Study type | Observational |
The main objectives of this study are to describe medical professionals responsible of the management of patients with MDD in a representative region of Andalusia (in terms of type of sites managing the disease, and referral to SC criteria); Describe MDD patient characteristics at inclusion in the PISMA-Ep Study; and to evaluate those factors associated to a higher incidence of referral from PC to SC.
| Status | Completed |
| Enrollment | 5309 |
| Est. completion date | September 2013 |
| Est. primary completion date | September 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - MDD Diagnosis Participants of the PismaEP study 18 yo. or older Exclusion Criteria: - No specific exclusion criteria |
Time Perspective: Retrospective
| Country | Name | City | State |
|---|---|---|---|
| Spain | Research Site | Granada |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Visits to Primary Care | From Jan 2010 to Jan 2011 | No | |
| Primary | Number of Visits to Secondary Care | From Jan 2010 to Jan 2011 | No | |
| Primary | Number of Referrals | From Jan 2010 to Jan 2011 | No | |
| Secondary | Demographics | From Jan 2010 to Jan 2011 | No | |
| Secondary | Type of site | From Jan 2010 to Jan 2011 | No | |
| Secondary | Type of therapeutic strategy | From Jan 2010 to Jan 2011 | No | |
| Secondary | Type of disease | From Jan 2010 to Jan 2011 | No | |
| Secondary | Severity of disease | From Jan 2010 to Jan 2011 | No |